ClinicalTrials.gg
RecruitingNCT04192656Updated Dec 10, 2019

The Effect of PAP on ISSHL Comorbided With OSA

A Phase 4 interventional study of non-invasive positive airway pressure and Methylprednisolone Hemisuccinate in Sudden Hearing Loss and Obstructive Sleep Apnea, sponsored by Beijing Tsinghua Chang Gung Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-12-10.

Sponsored by Beijing Tsinghua Chang Gung Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2019; still recruiting 7 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Hearing Loss, Sudden with a site in China — 11 open to participants now, 11 under way, 1 of them phase 3. Hearing Loss, Sudden · China.

Planned enrollment
7th of 15
102 · median 90
Started
2019
with 2 others
Phase 4
Only one
of the 18
Primary completion
2024-12
later than 1 of 10 live
Registered
4th of 18
by date
Lead sponsor
1 of 18
Beijing Tsinghua Chang Gung Hospital

Among the 18 studies in Hearing Loss, Sudden with a site in China, this one is the 7th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2019, is the only one in phase 4, reaches primary completion later than 1 of the 10 other live ones, and was the 4th registered.

Hearing Loss, Sudden

66 studies on the registry are indexed under Hearing Loss, Sudden; 25 are open to participants now.

Browse Hearing Loss, Sudden studies →

Open to participants now

11 of the 18 studies in Hearing Loss, Sudden with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Hearing Loss, Sudden studies recruiting now, 3 (30%) set no upper age limit and 5 (50%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hearing Loss, Sudden with a site in China, or all of them as a file.
02

Study summary

This clinical randomized controlled study is to explore the effect of positive airway pressure(PAP) on patients in Beijing Tsinghua Changgung Hospital diagnosed with both idiopathic sudden sensorineural hearing loss comorbided(ISSHL) and obstructive sleep apnea(OSA) between Dec. 2019 to Dec. 2029.

03

Conditions studied

  • Sudden Hearing Loss
  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. aged >= 18 and \<= 70,
  2. diagnosed with OSA by full-night in-lab or home-stay PSG according to AASM 2012 criteria, and AHI > 15/h,
  3. diagnosed with ISSHL by AAO-HNS 2019 criteria,
  4. ISSHL onset within 1 week.

Exclusion criteria

Exclusion Criteria:

  1. sudden hearing loss with certain causes,
  2. with severe comorbid diseases,
  3. pregnant or breast-feeding women,
  4. AHI \<= 15/h,
  5. hearing threshold recovered > 50% when included,
  6. previously regularly treated with PAP.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    PAP plus medication

    patients treated by both PAP and medication

    Device: non-invasive positive airway pressure · Drug: Methylprednisolone Hemisuccinate · Drug: Ginaton

  • Active comparator
    medication

    patients treated by medication only

    Drug: Methylprednisolone Hemisuccinate · Drug: Ginaton

Interventions

  • Devicenon-invasive positive airway pressure

    non-invasive positive airway pressure is the first-line treatment for obstructive sleep apnea

  • Methylprednisolone is the first-line treatment of idiopathic sudden sensorineural hearing loss

    Also known as: Methylprednisolone, MP

  • DrugGinaton

    ginnaton is ginkgo biloba extract

    Also known as: Ginkgo biloba extract,GBE

06

What researchers measure

Primary outcomes

  1. hearing threshold

    the recovery of hearing threshold which will be measured by pure tone audiometry

    Time frame: 3 months after onset of ISSHL

07

Study locations

1 of 1 sites recruiting
  • Beijing Tsinhgua Changgung Hospital
    Beijing, Beijing 100028, China
    Recruiting
08

References and documents

Publications

  • Hizli O, Ozcan M, Unal A. Evaluation of comorbidities in patients with OSAS and simple snoring. ScientificWorldJournal. 2013 Apr 18;2013:709292. doi: 10.1155/2013/709292. Print 2013. PubMed 23710145 ↗
  • Kayabasi S, Iriz A, Cayonu M, Cengiz B, Acar A, Boynuegri S, Mujdeci B, Eryilmaz A. Vestibular functions were found to be impaired in patients with moderate-to-severe obstructive sleep apnea. Laryngoscope. 2015 May;125(5):1244-8. doi: 10.1002/lary.25021. Epub 2014 Nov 12. PubMed 25388224 ↗
  • Casale M, Vesperini E, Potena M, Pappacena M, Bressi F, Baptista PJ, Salvinelli F. Is obstructive sleep apnea syndrome a risk factor for auditory pathway? Sleep Breath. 2012 Jun;16(2):413-7. doi: 10.1007/s11325-011-0517-x. Epub 2011 Apr 9. PubMed 21479758 ↗
  • Fu Q, Wang T, Liang Y, Lin Y, Zhao X, Wan J, Fan S. Auditory Deficits in Patients With Mild and Moderate Obstructive Sleep Apnea Syndrome: A Speech Syllable Evoked Auditory Brainstem Response Study. Clin Exp Otorhinolaryngol. 2019 Feb;12(1):58-65. doi: 10.21053/ceo.2018.00017. Epub 2018 Aug 24. PubMed 30134647 ↗
  • Sheu JJ, Wu CS, Lin HC. Association between obstructive sleep apnea and sudden sensorineural hearing loss: a population-based case-control study. Arch Otolaryngol Head Neck Surg. 2012 Jan;138(1):55-9. doi: 10.1001/archoto.2011.227. PubMed 22249630 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2019 (actual). Primary completion is estimated for Dec 2024, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2019
First posted
Dec 10, 2019
StartActual
Nov 1, 2019
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2029
Last update
Dec 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04192656
Responsible party
Ye Jingying (Director of the dept. of Otolaryngology, Head and Neck Surgery, and Director of the Center of Sleep Medicine, Beijing Tsinghua Chang Gung Hospital) — Principal investigator
First posted
Dec 10, 2019
Start date
Nov 1, 2019
Primary completion
Dec 2024 (estimated)
Completion
Dec 2029 (estimated)
Last update
Dec 10, 2019

Study contacts

Jingying Ye, MD
Contact
yejingying@163.vip.com
+86-13701396970
Haijin Yi, MD
Contact
Juanjuan Gao, MD
principal investigator · Beijing Tsinghua Changung Hospital
jingying Ye, MD
study chair · Beijing Tsinghua Changung Hospital
Haijin Yi, MD
study director · Beijing Tsinghua Changung Hospital
Mu He, MD
principal investigator · Beijing Tsinghua Changung Hospital
Xin Cao, MA
principal investigator · Beijing Tsinghua Changung Hospital
Xingxing Lu, MA
principal investigator · Beijing Tsinghua Changung Hospital
Sichao Liang, MA
principal investigator · Beijing Tsinghua Changung Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion